Ipca Laboratories subsidiary; manufactures APIs and formulations for Ipca and the US generics market.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 2.5k | 2.5k | 2.6k | 2.4k | 2.4k | 2.4k | 2.4k | 2.7k |
| Borrowings | 206 | 119 | 349 | 314 | 248 | 460 | 502 | 500 |
| Other Liabilities | 407 | 436 | 351 | 444 | 589 | 659 | 619 | 489 |
| Total Liabilities | 3.1k | 3.1k | 3.3k | 3.2k | 3.3k | 3.6k | 3.6k | 3.7k |
| AssetsFixed Assets | 870 | 884 | 990 | 1.3k | 1.3k | 1.3k | 1.2k | 1.2k |
| CWIP | 330 | 568 | 494 | 147 | 123 | 31 | 79 | 100 |
| Investments | 550 | 392 | 264 | 2 | 1 | 0 | 0 | 0 |
| Other Assets | 1.4k | 1.3k | 1.6k | 1.8k | 1.9k | 2.2k | 2.2k | 2.4k |
| Total Assets | 3.1k | 3.1k | 3.3k | 3.2k | 3.3k | 3.6k | 3.6k | 3.7k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | -328 | 20 | 33 | -260 | -85 | 14 | -7 | 4 |
| Cash from Investing | -286 | -36 | -66 | 100 | 241 | 63 | -242 | 194 |
| Cash from Financing | -2 | -62 | -121 | 191 | -81 | -106 | 184 | 2 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -519 | -360 | -254 | -386 | -123 | 0 | -142 | 163 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
UNICHEMLAB · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.